Please use this identifier to cite or link to this item:
Title: Promising application of metformin in Alzheimer's disease
Author: Rabiei Poor, Saghar
Ettcheto Arriola, Miren
Cano Fernández, Amanda
Sánchez-López, E. (Elena)
Manzine, Patrícia Regina
Olloquequi, Jordi
Camins Espuny, Antoni
Javan, Mohammad
Keywords: Malaltia d'Alzheimer
Resistència a la insulina
Alzheimer's disease
Insulin resistance
Issue Date: 1-Sep-2021
Publisher: MDPI
Abstract: Alzheimer's disease (AD) is one of the most devastating brain disorders. Currently, there are no effective treatments to stop the disease progression and it is becoming a major public health concern. Several risk factors are involved in the progression of AD, modifying neuronal circuits and brain cognition, and eventually leading to neuronal death. Among them, obesity and type 2 diabetes mellitus (T2DM) have attracted increasing attention, since brain insulin resistance can contribute to neurodegeneration. Consequently, AD has been referred to "type 3 diabetes" and antidiabetic medications such as intranasal insulin, glitazones, metformin or liraglutide are being tested as possible alternatives. Metformin, a first line antihyperglycemic medication, is a 5′-adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator hypothesized to act as a geroprotective agent. However, studies on its association with age-related cognitive decline have shown controversial results with positive and negative findings. In spite of this, metformin shows positive benefits such as anti-inflammatory effects, accelerated neurogenesis, strengthened memory, and prolonged life expectancy. Moreover, it has been recently demonstrated that metformin enhances synaptophysin, sirtuin-1, AMPK, and brain-derived neuronal factor (BDNF) immunoreactivity, which are essential markers of plasticity. The present review discusses the numerous studies which have explored (1) the neuropathological hallmarks of AD, (2) association of type 2 diabetes with AD, and (3) the potential therapeutic effects of metformin on AD and preclinical models. Keywords: Alzheimer's disease; diabetes mellitus; metformin; insulin resistance; beta amyloid; tau protein hyperphosphorylation; AMP activated protein kinase (AMPK)
Note: Reproducció del document publicat a:
It is part of: Pharmaceuticals, 2021, vol. 14, num. 9
Related resource:
ISSN: 1424-8247
Appears in Collections:Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Bioquímica i Fisiologia)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
714857.pdf748.86 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons